Steven J.  Rice net worth and biography

Steven Rice Biography and Net Worth

Insider of Vir Biotechnology
Steven Rice has served as our Chief Administrative Officer since August 2020. Mr. Rice is responsible for human resources, legal, information technology, facilities, and employee communications. Mr. Rice held the Chief Human Resources Officer position since joining Vir in September 2019. Prior to joining Vir, Mr. Rice was the Chief Human Resources Officer for the Bill & Melinda Gates Foundation from May 2015 to May 2019 where he led human resources, facilities, events, and travel. Prior to the Bill & Melinda Gates Foundation, Mr. Rice was the Executive Vice President of global human resources at Juniper Networks, Inc. from February 2006 to May 2015. Mr. Rice also chaired Juniper Networks’ Corporate Foundation. Additionally, Mr. Rice has held several human resources leadership positions at Hewlett-Packard Company from 1981 to 2006, including Vice President of Human Resources Global Operations. Mr. Rice received his A.A. in business administration and management from De Anza College.

What is Steven J. Rice's net worth?

The estimated net worth of Steven J. Rice is at least $1.08 million as of June 1st, 2023. Mr. Rice owns 106,840 shares of Vir Biotechnology stock worth more than $1,082,289 as of March 29th. This net worth evaluation does not reflect any other assets that Mr. Rice may own. Learn More about Steven J. Rice's net worth.

How do I contact Steven J. Rice?

The corporate mailing address for Mr. Rice and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at [email protected]. Learn More on Steven J. Rice's contact information.

Has Steven J. Rice been buying or selling shares of Vir Biotechnology?

Steven J. Rice has not been actively trading shares of Vir Biotechnology over the course of the past ninety days. Most recently, Steven J. Rice sold 2,500 shares of the business's stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $25.67, for a transaction totalling $64,175.00. Following the completion of the sale, the insider now directly owns 106,840 shares of the company's stock, valued at $2,742,582.80. Learn More on Steven J. Rice's trading history.

Who are Vir Biotechnology's active insiders?

Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.

Are insiders buying or selling shares of Vir Biotechnology?

In the last twelve months, insiders at the sold shares 30 times. They sold a total of 1,170,412 shares worth more than $29,043,010.48. The most recent insider tranaction occured on March, 27th when CFO Sung Lee sold 6,008 shares worth more than $59,419.12. Insiders at Vir Biotechnology own 18.1% of the company. Learn More about insider trades at Vir Biotechnology.

Information on this page was last updated on 3/27/2024.

Steven J. Rice Insider Trading History at Vir Biotechnology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/1/2023Sell2,500$25.67$64,175.00106,840View SEC Filing Icon  
2/17/2023Sell1,981$25.29$50,099.4937,209View SEC Filing Icon  
11/30/2021Sell10,000$50.00$500,000.00View SEC Filing Icon  
8/23/2021Sell10,000$50.00$500,000.0030,000View SEC Filing Icon  
6/25/2021Sell3$50.00$150.0020,003View SEC Filing Icon  
See Full Table

Steven J. Rice Buying and Selling Activity at Vir Biotechnology

This chart shows Steven J Rice's buying and selling at Vir Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vir Biotechnology Company Overview

Vir Biotechnology logo
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $10.13
Low: $10.03
High: $10.34

50 Day Range

MA: $10.18
Low: $8.60
High: $11.90

2 Week Range

Now: $10.13
Low: $7.72
High: $27.48

Volume

738,254 shs

Average Volume

1,100,224 shs

Market Capitalization

$1.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.42